HRTS Tema Heart & Health ETF
ETF on NASDAQ (US) · Actively managed · Listing
Most notable sale · Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited cut by 45%
Shares went from 30,273 to 16,554 ($1.07M → $597K). Now 1.1% of the portfolio. Estimated trade $495K.
Most notable buy · Kodiak Sciences Inc
New position in Kodiak Sciences Inc
33,234 shares worth $1.24M. Now 2.2% of the portfolio.
Largest holding: Eli Lilly and Company, cut 1%, 5,343 shares ($6.18M).
| Current positions Top 10 | % of book |
|---|---|
| Eli Lilly and Company LLY $6.18M · −1% sh | 11.1% |
| Thermo Fisher Scientific Inc TMO $2.85M · +10% sh | 5.1% |
| UnitedHealth Group Incorporated UNH $2.80M · +1% sh | 5.0% |
| Novo Nordisk A/S NOVOB $2.66M · −1% sh | 4.8% |
| Merck & Company, Inc. MRK $2.40M · −13% sh | 4.3% |
| Johnson & Johnson JNJ $2.17M · −1% sh | 3.9% |
| Roche Holding AG RHHBY $2.09M · −12% units | 3.8% |
| Revolution Medicines, Inc. RVMD $2.05M · −9% sh | 3.7% |
| Cytokinetics, Incorporated CYTK $1.96M · +62% sh | 3.5% |
| BridgeBio Pharma, Inc. BBIO $1.77M · +14% sh | 3.2% |
Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against May 31, 2026.
| Sectors | % of holdings value |
|---|---|
| Healthcare | 93.0% |
| Unclassified | 7.0% |
| Industries | % of holdings value |
|---|---|
| Drug Manufacturers - General | 33.8% |
| Biotechnology | 33.4% |
| Medical Devices | 13.8% |
| Medical Instruments & Supplies | 5.1% |
| Healthcare Plans | 5.0% |
| Medical Distribution | 1.9% |
| Unclassified | 7.0% |
| Initiations 3 | Value |
|---|---|
| Kodiak Sciences Inc KOD 2.2% of portfolio | $1.24M |
| Stryker Corporation SYK 1.3% of portfolio | $740K |
| Kailera Therapeutics, Inc. KLRA 0.4% of portfolio | $216K |
| Increases 7 | Change |
|---|---|
| Cytokinetics, Incorporated CYTK $1.31M → $1.96M | +62% |
| Intuitive Surgical, Inc. ISRG $675K → $1.21M | 2x |
| Thermo Fisher Scientific Inc TMO $2.06M → $2.85M | +10% |
| BridgeBio Pharma, Inc. BBIO $1.35M → $1.77M | +14% |
| Alnylam Pharmaceuticals, Inc. ALNY $590K → $618K | +31% |
| Danaher Corporation DHR $1.38M → $1.66M | +3% |
| UnitedHealth Group Incorporated UNH $2.72M → $2.80M | +1% |
| Reductions 35 | Change |
|---|---|
| Teva Pharmaceutical Industries Limited TEVA $1.07M → $597K | −45% |
| Amgen Inc. AMGN $992K → $817K | −35% |
| Regeneron Pharmaceuticals, Inc. REGN $866K → $742K | −34% |
| Merck & Company, Inc. MRK $2.22M → $2.40M | −13% |
| Roche Holding AG RHHBY $2.33M → $2.09M | −12% |
| MBX Biosciences, Inc. MBX $276K → $309K | −43% |
| DexCom, Inc. DXCM $996K → $1.01M | −18% |
| Revolution Medicines, Inc. RVMD $1.73M → $2.05M | −9% |
| Gilead Sciences, Inc. GILD $1.78M → $1.74M | −10% |
| Scholar Rock Holding Corporation SRRK $476K → $351K | −36% |
| AstraZeneca AZN $2.08M → $1.62M | −11% |
| Ionis Pharmaceuticals, Inc. IONS $428K → $146K | −57% |
| Terminations 2 | Change |
|---|---|
| Ascendis Pharma A/S ASND was $393K | −100% |
| Structure Therapeutics Inc. GPCR was $180K | −100% |
The other 23 reductions
Edwards Lifesciences Corporation (−18%), Vertex Pharmaceuticals Incorporated (−9%), Insmed Incorporated (−41%), Arrowhead Pharmaceuticals, Inc. (−27%), Novartis AG (−9%), AbbVie Inc. (−11%), Insulet Corporation (−36%), Eli Lilly and Company (−1%), Novo Nordisk A/S (−1%), Johnson & Johnson (−1%), Abbott Laboratories (−1%), Medtronic plc. (−1%), Bristol-Myers Squibb Company (−1%), McKesson Corporation (−1%), Madrigal Pharmaceuticals, Inc. (−1%), Chugai Pharmaceutical Co., Ltd. (−1%), Xenon Pharmaceuticals Inc. (−1%), Stoke Therapeutics, Inc. (−1%), Viking Therapeutics, Inc. (−1%), Boston Scientific Corporation (−<1%) and 3 more
Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Aug 31, 2026 (Form N-PORT) vs the portfolio of May 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the summary prospectus filed Jul 2, 2026.
Tema Heart & Health ETF (formerly, Tema GLP-1, Obesity & Cardiometabolic ETF) (the "Fund") seeks to provide long-term growth of capital.
Principal investment strategies
Under normal circumstances, the Fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions ("CDC"). GLP-1 (glucagon-like peptide) is a class of drugs that can help manage diabetes and obesity. The Adviser will apply this definition to internal research and analysis based on company disclosure (such as 10-K filings, company presentations, capital markets day presentations) and other publicly available sources (e.g., sell-side research, biotechnology industry publications etc.) to make this assessment. Example companies include large pharmaceutical firms, development-stage biotechnology companies, diagnostic focused businesses with products used to diagnose and/or treat the aforementioned diseases, medical device companies focused on treatment of the aforementioned diseases, and healthcare service providers with a specific strategic focus on helping treat and manage the aforementioned diseases, each providing they meet the aforementioned revenue test. 1 The Fund generally is expected to consist of more than 15 companies but not more than 100 companies. The number of constituents may change depending on the number of companies available for investment that meet the Fund's criteria. To be eligible for inclusion in the Fund, a company must have a market capitalization of at least $100 million and there is no upper limit on the market capitalization of a portfolio company. To be eligible for inclusion in the Fund, a company must have a three-month average daily traded value of at least $500,000. A significant portion of the Fund's assets are expected to be invested in the United States and Europe. The Fund will not engage in currency hedging and is expected to own foreign currency for short periods of time for the purposes of buying and selling non-US listed securities and collecting dividends and/or coupon payments from those securities. The Fund is classified as a "non-diversified" investment company under the Investment Company Act of 1940, as amended (the "1940 Act"), which means that it may invest a high percentage of its assets in a limited number of issuers and sectors. The basic investment philosophy of the Adviser is to seek to invest in growth companies within the aforementioned thematic universe that are attractively valued when compared to their fundamentals and potential for earnings growth. Tema ETF LLC's (the "Adviser"), the Fund's investment adviser, security selection process for identifying companies within the aforementioned theme uses both "top down" idea generation (sector, theme, company research) and "bottom up" security selection (valuation, fundamental, quantitative, qualitative measures) approaches. In practice "top down" idea generation means fundamental sector research, quantitative tools (for example screening based on metrics such as five-year historic revenue growth, margins, or returns on invested capital) and the Adviser's own expertise, are used to narrow down the specific thematic research universe. Once this is defined "bottom up" security analysis involves the Adviser comparing valuation multiples (such as free cash flow yield, price to book ratio and price to earnings ratio or enterprise to total invested capital, among others) to fundamental metrics (such as organic revenue growth, margins, returns on invested capital and equity, among others). Investments are deemed attractively valued when compared to fundamentals if the valuation multiples are below and fundamentals are above either (1) peers (2) the companies own historic averages (3) or prospective forecasts (as determined by the Adviser).
Management and Contact
- Adviser
- Tema ETFs LLC
- Sub-adviser
- Tidal Investments LLC
- Portfolio managers
-
David Song,Yuri Khodjamirian and Mauritis Pot (all since inception, November 2023).
Sub-Adviser – Tidal Investments LLC .
Portfolio Managers – Qiao Duan and Andy Hicks (since February 2026.
- Phone
- 1.888.744.1377
- Website
- temaetfs.com
Track Record as of Feb 28, 2026
Average annual total returns from the summary prospectus. Returns in percent; periods over a year are annualized.
| 1 Year | Since Inception | |
|---|---|---|
| Return Before Taxes | 23.64% | 16.18% |
| Return After Taxes on Distributions | 23.24% | 15.70% |
| Return After Taxes on Distributions and Sale of Fund Shares | 14.27% | 12.43% |
| S&P 500 Total Return Index | 17.88% | 23.00% |
Holdings as of Aug 31, 2026
The full portfolio as of the quarter end Aug 31, 2026, from the fund's report to the SEC (Form N-PORT, filed Oct 30, 2026), the newest we have: we do not read a daily file from this fund's website, or the filing is newer. Every line is listed: holdings we could identify link to their page, the rest (bonds, CLOs, loans, derivatives, securities we do not carry) are shown as filed, debt with its coupon and maturity; Shares is the principal amount for debt. Short positions are negative. Change is the share count against the filing of May 31, 2026.
46 lines, 43 linked, weights sum to 99.92% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | LLY US5324571083 | Equity | 5,343 | −70 | 11.11% | $ 6.18M |
| Thermo Fisher Scientific Inc | TMO US8835561023 | Equity | 4,616 | +431 | 5.12% | $ 2.849M |
| UnitedHealth Group Inc | UNH US91324P1021 | Equity | 7,195 | +36 | 5.04% | $ 2.802M |
| Novo Nordisk A/S | NOVOB DK0062498333 | Equity | 58,624 | −831 | 4.79% | $ 2.664M |
| Merck & Co Inc | MRK US58933Y1055 | Equity | 16,233 | −2,439 | 4.31% | $ 2.399M |
| Johnson & Johnson | JNJ US4781601046 | Equity | 8,166 | −108 | 3.90% | $ 2.171M |
|
Roche Holding AG
|
RHHBY US7711951043 | Equity | 38,978 | −5,560 | 3.76% | $ 2.093M |
| Revolution Medicines Inc | RVMD US76155X1000 | Equity | 9,951 | −1,020 | 3.68% | $ 2.046M |
| Cytokinetics Inc | CYTK US23282W6057 | Equity | 27,649 | +10,580 | 3.53% | $ 1.961M |
| Bridgebio Pharma Inc | BBIO US10806X1028 | Equity | 23,113 | +2,786 | 3.18% | $ 1.77M |
| Gilead Sciences Inc | GILD US3755581036 | Equity | 11,884 | −1,377 | 3.13% | $ 1.739M |
| Abbott Laboratories | ABT US0028241000 | Equity | 15,601 | −208 | 3.10% | $ 1.722M |
| Vertex Pharmaceuticals Inc | VRTX US92532F1003 | Equity | 3,079 | −319 | 3.02% | $ 1.677M |
| Danaher Corp | DHR US2358511028 | Equity | 7,756 | +199 | 2.98% | $ 1.656M |
| AstraZeneca PLC | AZN GB0009895292 | Equity | 9,969 | −1,209 | 2.91% | $ 1.617M |
|
Novartis AG
|
NOVN CH0012005267 | Equity | 10,564 | −1,063 | 2.90% | $ 1.611M |
| AbbVie Inc | ABBV US00287Y1091 | Equity | 5,088 | −626 | 2.35% | $ 1.305M |
| Bristol-Myers Squibb Co | BMY US1101221083 | Equity | 18,719 | −220 | 2.25% | $ 1.251M |
| Kodiak Sciences Inc | KOD US50015M1099 | Equity | 33,234 | new +33,234 | 2.23% | $ 1.241M |
| Intuitive Surgical Inc | ISRG US46120E6023 | Equity | 3,200 | +1,610 | 2.17% | $ 1.206M |
| Medtronic PLC | MDT IE00BTN1Y115 | Equity | 13,029 | −174 | 2.12% | $ 1.181M |
| McKesson Corp | MCK US58155Q1031 | Equity | 1,182 | −14 | 1.88% | $ 1.046M |
| Dexcom Inc | DXCM US2521311074 | Equity | 11,085 | −2,427 | 1.82% | $ 1.009M |
| Amgen Inc | AMGN US0311621009 | Equity | 1,901 | −1,045 | 1.47% | $ 817.202K |
| Madrigal Pharmaceuticals Inc | MDGL US5588681057 | Equity | 1,499 | −20 | 1.46% | $ 809.505K |
| Edwards Lifesciences Corp | EW US28176E1082 | Equity | 8,572 | −1,916 | 1.40% | $ 777.909K |
| Regeneron Pharmaceuticals Inc | REGN US75886F1075 | Equity | 929 | −479 | 1.34% | $ 742.345K |
| Stryker Corp | SYK US8636671013 | Equity | 2,284 | new +2,284 | 1.33% | $ 739.559K |
| Boston Scientific Corp | BSX US1011371077 | Equity | 15,214 | −71 | 1.32% | $ 734.836K |
| Alnylam Pharmaceuticals Inc | ALNY US02043Q1076 | Equity | 2,566 | +612 | 1.11% | $ 617.611K |
| Teva Pharmaceutical Industries | TEVA US8816242098 | Equity | 16,554 | −13,719 | 1.07% | $ 596.772K |
| Chugai Pharmaceutical Co Ltd | 4519 JP3519400000 | Equity | 13,731 | −184 | 1.07% | $ 594.193K |
| Xenon Pharmaceuticals Inc | XENE CA98420N1050 | Equity | 8,283 | −110 | 0.90% | $ 498.802K |
| Arrowhead Pharmaceuticals Inc | ARWR US04280A1007 | Equity | 5,263 | −1,977 | 0.78% | $ 433.619K |
| Scholar Rock Holding Corp | SRRK US80706P1030 | Equity | 6,177 | −3,470 | 0.63% | $ 350.854K |
| Stoke Therapeutics Inc | STOK US86150R1077 | Equity | 9,917 | −132 | 0.56% | $ 309.41K |
| MBX Biosciences Inc | MBX US55287L1017 | Equity | 5,010 | −3,751 | 0.56% | $ 308.616K |
| Viking Therapeutics Inc | VKTX US92686J1060 | Equity | 8,426 | −112 | 0.50% | $ 276.204K |
| Insulet Corp | PODD US45784P1012 | Equity | 1,827 | −1,008 | 0.49% | $ 271.602K |
| Gubra A/S | GUBRA DK0062266474 | Equity | 4,429 | −58 | 0.47% | $ 261.11K |
| Insmed Inc | INSM US4576693075 | Equity | 2,038 | −1,411 | 0.45% | $ 248.269K |
| Zealand Pharma A/S | ZEAL DK0060257814 | Equity | 5,223 | −70 | 0.44% | $ 243.479K |
| Kailera Therapeutics Inc | KLRA US4829311020 | Equity | 14,039 | new +14,039 | 0.39% | $ 216.201K |
|
First American Treasury Obliga
|
FXFXX US31846V3289 | Money market | 195,957.05 | −177,539.65 | 0.35% | $ 195.957K |
| Intellia Therapeutics Inc | NTLA US45826J1051 | Equity | 13,708 | −184 | 0.31% | $ 174.503K |
| Ionis Pharmaceuticals Inc | IONS US4622221004 | Equity | 2,427 | −3,172 | 0.26% | $ 146.494K |
Trades May 31, 2026 to Aug 31, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|---|---|---|---|---|---|
| Kodiak Sciences Inc | KOD | New | — | 33,234 | +33,234 | $ 1.241M |
| Cytokinetics Inc | CYTK | Bought | 17,069 | 27,649 | +10,580 | $ 750.228K |
| Stryker Corp | SYK | New | — | 2,284 | +2,284 | $ 739.559K |
| Intuitive Surgical Inc | ISRG | Bought | 1,590 | 3,200 | +1,610 | $ 606.745K |
| Teva Pharmaceutical Industries | TEVA | Sold | 30,273 | 16,554 | −13,719 | $ -494.57K |
| Amgen Inc | AMGN | Sold | 2,946 | 1,901 | −1,045 | $ -449.225K |
| Ascendis Pharma A/S | ASND | Closed | 1,755 | — | −1,755 | $ -393.313K |
| Regeneron Pharmaceuticals Inc | REGN | Sold | 1,408 | 929 | −479 | $ -382.759K |
| Merck & Co Inc | MRK | Sold | 18,672 | 16,233 | −2,439 | $ -360.387K |
|
Roche Holding AG
|
RHHBY | Sold | 44,538 | 38,978 | −5,560 | $ -298.572K |
| Thermo Fisher Scientific Inc | TMO | Bought | 4,185 | 4,616 | +431 | $ 265.97K |
| MBX Biosciences Inc | MBX | Sold | 8,761 | 5,010 | −3,751 | $ -231.062K |
| Dexcom Inc | DXCM | Sold | 13,512 | 11,085 | −2,427 | $ -221.003K |
| Kailera Therapeutics Inc | KLRA | New | — | 14,039 | +14,039 | $ 216.201K |
| Bridgebio Pharma Inc | BBIO | Bought | 20,327 | 23,113 | +2,786 | $ 213.38K |
| Revolution Medicines Inc | RVMD | Sold | 10,971 | 9,951 | −1,020 | $ -209.681K |
| Gilead Sciences Inc | GILD | Sold | 13,261 | 11,884 | −1,377 | $ -201.51K |
| Scholar Rock Holding Corp | SRRK | Sold | 9,647 | 6,177 | −3,470 | $ -197.096K |
| AstraZeneca PLC | AZN | Sold | 11,178 | 9,969 | −1,209 | $ -196.091K |
| Ionis Pharmaceuticals Inc | IONS | Sold | 5,599 | 2,427 | −3,172 | $ -191.462K |
| Structure Therapeutics Inc | GPCR | Closed | 4,583 | — | −4,583 | $ -180.295K |
| Edwards Lifesciences Corp | EW | Sold | 10,488 | 8,572 | −1,916 | $ -173.877K |
| Vertex Pharmaceuticals Inc | VRTX | Sold | 3,398 | 3,079 | −319 | $ -173.702K |
| Insmed Inc | INSM | Sold | 3,449 | 2,038 | −1,411 | $ -171.888K |
| Arrowhead Pharmaceuticals Inc | ARWR | Sold | 7,240 | 5,263 | −1,977 | $ -162.885K |
|
Novartis AG
|
NOVN | Sold | 11,627 | 10,564 | −1,063 | $ -162.09K |
| AbbVie Inc | ABBV | Sold | 5,714 | 5,088 | −626 | $ -160.519K |
| Insulet Corp | PODD | Sold | 2,835 | 1,827 | −1,008 | $ -149.849K |
| Alnylam Pharmaceuticals Inc | ALNY | Bought | 1,954 | 2,566 | +612 | $ 147.302K |
| Eli Lilly & Co | LLY | Sold | 5,413 | 5,343 | −70 | $ -80.971K |
| Danaher Corp | DHR | Bought | 7,557 | 7,756 | +199 | $ 42.498K |
| Novo Nordisk A/S | NOVOB | Sold | 59,455 | 58,624 | −831 | $ -37.757K |
| Johnson & Johnson | JNJ | Sold | 8,274 | 8,166 | −108 | $ -28.712K |
| Abbott Laboratories | ABT | Sold | 15,809 | 15,601 | −208 | $ -22.955K |
| Medtronic PLC | MDT | Sold | 13,203 | 13,029 | −174 | $ -15.773K |
| Bristol-Myers Squibb Co | BMY | Sold | 18,939 | 18,719 | −220 | $ -14.698K |
| UnitedHealth Group Inc | UNH | Bought | 7,159 | 7,195 | +36 | $ 14.019K |
| McKesson Corp | MCK | Sold | 1,196 | 1,182 | −14 | $ -12.394K |
| Madrigal Pharmaceuticals Inc | MDGL | Sold | 1,519 | 1,499 | −20 | $ -10.801K |
| Chugai Pharmaceutical Co Ltd | 4519 | Sold | 13,915 | 13,731 | −184 | $ -7,962.39 |
| Xenon Pharmaceuticals Inc | XENE | Sold | 8,393 | 8,283 | −110 | $ -6,624.20 |
| Stoke Therapeutics Inc | STOK | Sold | 10,049 | 9,917 | −132 | $ -4,118.40 |
| Viking Therapeutics Inc | VKTX | Sold | 8,538 | 8,426 | −112 | $ -3,671.36 |
| Boston Scientific Corp | BSX | Sold | 15,285 | 15,214 | −71 | $ -3,429.30 |
| Gubra A/S | GUBRA | Sold | 4,487 | 4,429 | −58 | $ -3,419.37 |
| Zealand Pharma A/S | ZEAL | Sold | 5,293 | 5,223 | −70 | $ -3,263.18 |
| Intellia Therapeutics Inc | NTLA | Sold | 13,892 | 13,708 | −184 | $ -2,342.32 |
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up